Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 28005582 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | drug-induced liver injury | NA | NA | NA | unclassified | |
| the aim of the present study is to analyse the genetic factors (human leukocyte antigen [hla], cytokine polymorphisms, and killer cell immunoglobulin-like receptor [kir] genotype) of children who experience an episode of drug-induced liver injury. | |||||||
| 28028769 | HLA (HLA) | drug-induced liver injury | NA | isoniazid | NA | unclassified | |
| despite considerable progress in identifying specific hla alleles as genetic risk factors for some forms of drug-induced liver injury, progress in understanding whether genetic polymorphisms relevant to drug disposition also contribute to risk for developing this serious toxicity has been more limited. | |||||||
| 28028769 | HLA (HLA) | drug-induced liver injury | NA | isoniazid | NA | negation | |
| a better understanding of genetic risk factors for drug-induced liver injury will require further genome-wide association studies with larger numbers of cases, especially for forms of drug-induced liver injury where hla genotype does not appear to be a risk factor. | |||||||
| 30661239 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | flucloxacillin | NA | amoxicillin | NA | unclassified | |
| NA | |||||||
| 31388624 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | drug-induced liver injury | Caucasian | NA | rs1421085 | unclassified | |
| the aim of the current study was to determine whether selected single nucleotide polymorphisms (snps) unrelated to the human leukocyte antigen region or other immune pathways, including those associated with nonalcoholic fatty liver disease (nafld), may influence development, severity, or outcomes of drug-induced liver injury (dili). | |||||||
| 31388624 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | nonalcoholic fatty liver disease | Caucasian | NA | rs1421085 | unclassified | |
| the aim of the current study was to determine whether selected single nucleotide polymorphisms (snps) unrelated to the human leukocyte antigen region or other immune pathways, including those associated with nonalcoholic fatty liver disease (nafld), may influence development, severity, or outcomes of drug-induced liver injury (dili). | |||||||
| 31784402 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | drug-induced liver injury | NA | NA | NA | unclassified | |
| research advances in the association of drug-induced liver injury with polymorphisms in human leukocyte antigen. | |||||||
| 31784402 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | drug-induced liver injury | NA | NA | NA | unclassified | |
| the article reviews the relevant advances in the association between novel human leukocyte antigen gene polymorphisms and drug-induced liver injury in order to identify potential biomarkers and provide a new method for the prediction and diagnosis of drug-induced liver injury. | |||||||
| 31905014 | NA (NA) | NA | European | rs1050450 | rs4880 | unclassified | |
| NA | |||||||
| 32130375 | HLA-B (HLA-B) | drug-induced liver injury | NA | flucloxacillin | NA | unclassified | |
| the authors present this case to remind the possibility of moderate/severe drug-induced liver injury to flucloxacillin, an antibiotic commonly used in clinical practice and association with the hla-b * 5701 allele reported in the literature. | |||||||
Copyright 2024